Crinetics Pharmaceuticals Inc (CRNX) USD0.001
Crinetics Pharmaceuticals, Inc. is a United States-based therapeutics company. The Company is focused on discovery, development, and commercialization of oral nonpeptide therapeutics for endocrine diseases and endocrine-related tumors. It uses a pipeline of oral nonpeptide (small molecule) new chemical entities that targets peptide G protein coupled receptors (GPCRs) to treat a variety of endocrine diseases. The Company's product range includes CRN00808, for the treatment of acromegaly; CRN02481, for the treatment of hyperinsulinemias; CRN01941, for the treatment of neuroendocrine tumors (NETs).
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.